Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Clarius Group LLC

Clarius Group LLC trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.3% in the 4th quarter, HoldingsChannel reports. The firm owned 620 shares of the biopharmaceutical company’s stock after selling 21 shares during the period. Clarius Group LLC’s holdings in Regeneron Pharmaceuticals were worth $442,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of REGN. State Street Corp grew its position in shares of Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after buying an additional 61,277 shares in the last quarter. International Assets Investment Management LLC grew its holdings in Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after acquiring an additional 879,916 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock valued at $707,759,000 after purchasing an additional 11,499 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Regeneron Pharmaceuticals by 0.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 340,566 shares of the biopharmaceutical company’s stock valued at $357,945,000 after purchasing an additional 2,270 shares during the last quarter. Finally, Swiss National Bank raised its holdings in shares of Regeneron Pharmaceuticals by 0.6% in the 3rd quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock valued at $338,079,000 after purchasing an additional 2,000 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the subject of a number of analyst reports. Evercore ISI lowered their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Morgan Stanley lowered their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Finally, Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,015.38.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $681.58 on Monday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $666.25 and a 12-month high of $1,211.20. The company has a market cap of $74.90 billion, a price-to-earnings ratio of 16.87, a price-to-earnings-growth ratio of 1.60 and a beta of 0.10. The stock has a 50 day simple moving average of $738.60 and a 200-day simple moving average of $949.32.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.